Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Cell Death Dis. 2020 Oct 9;11(10):841. doi: 10.1038/s41419-020-03062-z.
Mitochondrial ClpP is a serine protease located in the mitochondrial matrix. This protease participates in mitochondrial protein quality control by degrading misfolded or damaged proteins, thus maintaining normal metabolic function. Mitochondrial ClpP is a stable heptamer ring with peptidase activity that forms a multimeric complex with the ATP-dependent unfoldase ClpX (ClpXP) leading to proteolytic activity. Emerging evidence demonstrates that ClpXP is over-expressed in hematologic malignancies and solid tumors and is necessary for the viability of a subset of tumors. In addition, both inhibition and hyperactivation of ClpXP leads to impaired respiratory chain activity and causes cell death in cancer cells. Therefore, targeting mitochondrial ClpXP could be a novel therapeutic strategy for the treatment of malignancy. Here, we review the structure and function of mitochondrial ClpXP as well as strategies to target this enzyme complex as a novel therapeutic approach for malignancy.
线粒体 ClpP 是一种位于线粒体基质中的丝氨酸蛋白酶。这种蛋白酶通过降解错误折叠或受损的蛋白质参与线粒体蛋白质质量控制,从而维持正常的代谢功能。线粒体 ClpP 是一种具有肽酶活性的稳定七聚体环,与依赖 ATP 的解旋酶 ClpX(ClpXP)形成多聚体复合物,从而具有蛋白水解活性。新出现的证据表明,ClpXP 在血液恶性肿瘤和实体瘤中过度表达,并且是一部分肿瘤存活所必需的。此外,ClpXP 的抑制和过度激活都会导致呼吸链活性受损,并导致癌细胞死亡。因此,靶向线粒体 ClpXP 可能是治疗恶性肿瘤的一种新的治疗策略。在这里,我们综述了线粒体 ClpXP 的结构和功能,以及将该酶复合物作为一种新的治疗恶性肿瘤的方法的靶向策略。